Ludovic Breasson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ludovic Breasson has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Giovanni Solinas
The Wallenberg Laboratory, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
5 shared publications - Barbara Becattini
The Wallenberg Laboratory, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
4 shared publications Claudia Sardi
The Wallenberg Laboratory, Department of Molecular and Clinical Medicine at Institute of Medicine, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden
4 shared publicationsFabio Zani
The Francis Crick Institute, London, UK
3 shared publications- Alessandro Provenzani
University of Trento
2 shared publications - Fabio Zani
Department of Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada
2 shared publications
Latest Publications
- Open Access
- 2 September 2021
- Published by Elsevier in JHEP Reports
- Vol. 3 (6) , 100359
PI3Kγ promotes obesity-associated hepatocellular carcinoma by regulating metabolism and inflammation
- 2 September 2021
- Published by Elsevier in JHEP Reports
- Vol. 3 (6) , 100359
Open AccessPI3Kγ promotes obesity-associated hepatocellular carcinoma by regulating metabolism and inflammation
- Open Access
- 13 September 2017
- Published by Wiley in The FASEB Journal
- Vol. 32 (1) , 319-329
PI3Kγ ablation does not promote diabetes in db/db mice, but improves insulin sensitivity and reduces pancreatic β‐cell apoptosis
PI3Kγ has emerged as a promising target for the treatment of obesity and insulin resistance; however, previous studies have indicated that PI3Kγ activity in pancreatic β cells is required for normal insulin secretion in response to glucose. Hence, a possible deterioration of insulin secretion capacity in patients who are predisposed to the failure of pancreatic β‐cell function is a major concern for the pharmacologic inhibition of PI3Kγ. To address this issue, we investigated the effects of PI3Kγ ablation in db/db diabetic mice, a genetic model of obesity‐driven β‐cell failure and diabetes. Mice that lacked PI3Kγ were backcrossed into db/+ mice C57BL/KS (>10 generations) to obtain db/db‐PI3Kγ‐/‐ mice. db/db‐PI3Kγ‐/‐ mice and control db/db mice were phenotyped for glucose homeostasis, insulin sensitivity, insulin secretion, steatosis, metabolic inflammation, pancreatic islet morphometry, islet cellular composition, and inflammation. Pancreatic p‐cell apoptosis and proliferation were also evaluated. db/db‐PI3K γ‐/‐ mice and control db/db mice developed similar body weight, steatosis, glycemia, and insulin levels after a glucose load; however, db/db‐PI3Kγ‐/‐ mice displayed improved insulin tolerance, higher levels of fasting serum insulin, and lower pancreatic insulin content. In db/db‐PI3Kγ‐/‐ mice, the number of adipose tissue macrophages was similar to control, but displayed reduced adipose tissue neutrophils and M2‐polarized adipose tissue gene expression. Finally, db/db‐PI3K γ‐/‐ mice have more pancreatic β cells and larger islets than db/db mice, despite displaying similar islet inflammation. This phenotype could be explained by reduced β‐cell apoptosis in db/db‐PI3K γ‐/‐ mice compared with control db/db mice. Our results are consistent with the concept that the beneficial action of PI3Kγ ablation in obesity‐driven glucose intolerance is largely a result of its leptin‐dependent effects on adiposity and, to a lesser extent, the promotion of adipose tissue neutrophil recruitment and M1 polarization of gene expression. Of importance, our data challenge the concept that PI3Kγ is required for insulin secretion in response to glucose in vivo , and indicate that PI3Kγ ablation protects db/db mice from β‐cell apoptosis and improves fasting insulin levels. We conclude that PI3Kγ inhibition in obese patients who are predisposed to β‐cell failure is not expected to produce adverse effects on insulin secretion.—Breasson, L., Sardi, C., Becattini, B., Zani, F., Solinas, G. PI3Kγ ablation does not promote diabetes in db/db mice, but improves insulin sensitivity and reduces pancreatic β‐cell apoptosis. FASEB J. 32, 319‐329 (2018). www.fasebj.org
- 13 September 2017
- Published by Wiley in The FASEB Journal
- Vol. 32 (1) , 319-329
Open AccessPI3Kγ ablation does not promote diabetes in db/db mice, but improves insulin sensitivity and reduces pancreatic β‐cell apoptosis
PI3Kγ has emerged as a promising target for the treatment of obesity and insulin resistance; however, previous studies have indicated that PI3Kγ activity in pancreatic β cells is required for normal insulin secretion in response to glucose. Hence, a possible deterioration of insulin secretion capacity in patients who are predisposed to the failure of pancreatic β‐cell function is a major concern for the pharmacologic inhibition of PI3Kγ. To address this issue, we investigated the effects of PI3Kγ ablation in db/db diabetic mice, a genetic model of obesity‐driven β‐cell failure and diabetes. Mice that lacked PI3Kγ were backcrossed into db/+ mice C57BL/KS (>10 generations) to obtain db/db‐PI3Kγ‐/‐ mice. db/db‐PI3Kγ‐/‐ mice and control db/db mice were phenotyped for glucose homeostasis, insulin sensitivity, insulin secretion, steatosis, metabolic inflammation, pancreatic islet morphometry, islet cellular composition, and inflammation. Pancreatic p‐cell apoptosis and proliferation were also evaluated. db/db‐PI3K γ‐/‐ mice and control db/db mice developed similar body weight, steatosis, glycemia, and insulin levels after a glucose load; however, db/db‐PI3Kγ‐/‐ mice displayed improved insulin tolerance, higher levels of fasting serum insulin, and lower pancreatic insulin content. In db/db‐PI3Kγ‐/‐ mice, the number of adipose tissue macrophages was similar to control, but displayed reduced adipose tissue neutrophils and M2‐polarized adipose tissue gene expression. Finally, db/db‐PI3K γ‐/‐ mice have more pancreatic β cells and larger islets than db/db mice, despite displaying similar islet inflammation. This phenotype could be explained by reduced β‐cell apoptosis in db/db‐PI3K γ‐/‐ mice compared with control db/db mice. Our results are consistent with the concept that the beneficial action of PI3Kγ ablation in obesity‐driven glucose intolerance is largely a result of its leptin‐dependent effects on adiposity and, to a lesser extent, the promotion of adipose tissue neutrophil recruitment and M1 polarization of gene expression. Of importance, our data challenge the concept that PI3Kγ is required for insulin secretion in response to glucose in vivo , and indicate that PI3Kγ ablation protects db/db mice from β‐cell apoptosis and improves fasting insulin levels. We conclude that PI3Kγ inhibition in obese patients who are predisposed to β‐cell failure is not expected to produce adverse effects on insulin secretion.—Breasson, L., Sardi, C., Becattini, B., Zani, F., Solinas, G. PI3Kγ ablation does not promote diabetes in db/db mice, but improves insulin sensitivity and reduces pancreatic β‐cell apoptosis. FASEB J. 32, 319‐329 (2018). www.fasebj.org
- 18 July 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 10 (488)
PI3Kγ activity in leukocytes promotes adipose tissue inflammation and early-onset insulin resistance during obesity
The kinase PI3Kγ aggravates obesity by activating macrophages and triggering inflammation in adipose tissue.
- 18 July 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 10 (488)
PI3Kγ activity in leukocytes promotes adipose tissue inflammation and early-onset insulin resistance during obesity
The kinase PI3Kγ aggravates obesity by activating macrophages and triggering inflammation in adipose tissue.
- Open Access
- 26 May 2016
- Published by Wiley in The FASEB Journal
- Vol. 30 (9) , 3124-3132
JNK1 ablation in mice confers long‐term metabolic protection from diet‐induced obesity at the cost of moderate skin oxidative damage
Obesity and insulin resistance are associated with oxidative stress, which may be implicated in the progression of obesity‐related diseases. The kinase JNK1 has emerged as a promising drug target for the treatment of obesity and type 2 diabetes. JNK1 is also a key mediator of the oxidative stress response, which can promote cell death or survival, depending on the magnitude and context of its activation. In this article, we describe a study in which the long‐term effects of JNK1 inactivation on glucose homeostasis and oxidative stress in obese mice were investigated for the first time. Mice lacking JNK1 (JNK1 –/– ) were fed an obesogenic high‐fat diet (HFD) for a long period. JNK1 –/– mice fed an HFD for the long term had reduced expression of antioxidant genes in their skin, more skin oxidative damage, and increased epidermal thickness and inflammation compared with the effects in control wild‐type mice. However, we also observed that the protection from obesity, adipose tissue inflammation, steatosis, and insulin resistance, conferred by JNK1 ablation, was sustained over a long period and was paralleled by decreased oxidative damage in fat and liver. We conclude that compounds targeting JNK1 activity in brain and adipose tissue, which do not accumulate in the skin, may be safer and most effective.—Becattini, B., Zani, F., Breasson, L., Sardi, C., D'Agostino, V. G., Choo, M.‐K., Provenzani, A., Park, J. M., Solinas, G. JNK1 ablation in mice confers long‐term metabolic protection from diet‐induced obesity at the cost of moderate skin oxidative damage. FASEBJ. 30, 3124–3132 (2016). www.fasebj.org
- 26 May 2016
- Published by Wiley in The FASEB Journal
- Vol. 30 (9) , 3124-3132
Open AccessJNK1 ablation in mice confers long‐term metabolic protection from diet‐induced obesity at the cost of moderate skin oxidative damage
Obesity and insulin resistance are associated with oxidative stress, which may be implicated in the progression of obesity‐related diseases. The kinase JNK1 has emerged as a promising drug target for the treatment of obesity and type 2 diabetes. JNK1 is also a key mediator of the oxidative stress response, which can promote cell death or survival, depending on the magnitude and context of its activation. In this article, we describe a study in which the long‐term effects of JNK1 inactivation on glucose homeostasis and oxidative stress in obese mice were investigated for the first time. Mice lacking JNK1 (JNK1 –/– ) were fed an obesogenic high‐fat diet (HFD) for a long period. JNK1 –/– mice fed an HFD for the long term had reduced expression of antioxidant genes in their skin, more skin oxidative damage, and increased epidermal thickness and inflammation compared with the effects in control wild‐type mice. However, we also observed that the protection from obesity, adipose tissue inflammation, steatosis, and insulin resistance, conferred by JNK1 ablation, was sustained over a long period and was paralleled by decreased oxidative damage in fat and liver. We conclude that compounds targeting JNK1 activity in brain and adipose tissue, which do not accumulate in the skin, may be safer and most effective.—Becattini, B., Zani, F., Breasson, L., Sardi, C., D'Agostino, V. G., Choo, M.‐K., Provenzani, A., Park, J. M., Solinas, G. JNK1 ablation in mice confers long‐term metabolic protection from diet‐induced obesity at the cost of moderate skin oxidative damage. FASEBJ. 30, 3124–3132 (2016). www.fasebj.org
- Open Access
- 1 August 2013
- Published by Elsevier in Molecular Metabolism
- Vol. 2 (3) , 292-305
PER2 promotes glucose storage to liver glycogen during feeding and acute fasting by inducing Gys2 PTG and GL expression
- 1 August 2013
- Published by Elsevier in Molecular Metabolism
- Vol. 2 (3) , 292-305
Open AccessPER2 promotes glucose storage to liver glycogen during feeding and acute fasting by inducing Gys2 PTG and GL expression
- 1 July 2013
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 31 (7) , 1309-1320
Native Adipose Stromal Cells Egress from Adipose Tissue In Vivo: Evidence During Lymph Node Activation
Adipose tissue (AT) has become accepted as a source of multipotent progenitor cells, the adipose stromal cells (ASCs). In this regard, considerable work has been performed to harvest and characterize this cell population as well as to investigate the mechanisms by which transplanted ASCs mediate tissue regeneration. In contrast the endogenous release of native ASCs by AT has been poorly investigated. In this work, we show that native ASCs egress from murine AT. Indeed, we demonstrated that the release of native ASCs from AT can be evidenced both using an ex vivo perfusion model that we set up and in vivo. Such a mobilization process is controlled by CXCR4 chemokine receptor. In addition, once mobilized from AT, circulating ASCs were found to navigate through lymph fluid and to home into lymph nodes (LN). Therefore, we demonstrated that, during the LN activation, the fat depot encapsulating the activated LN releases native ASCs, which in turn invade the activated LN. Moreover, the ASCs invading the LN were visualized in close physical interaction with podoplanin and ER-TR7 positive structures corresponding to the stromal network composing the LN. This dynamic was impaired with CXCR4 neutralizing antibody. Taken together, these data provide robust evidences that native ASCs can traffic in vivo and that AT might provide stromal cells to activated LNs.
- 1 July 2013
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 31 (7) , 1309-1320
Native Adipose Stromal Cells Egress from Adipose Tissue In Vivo: Evidence During Lymph Node Activation
Adipose tissue (AT) has become accepted as a source of multipotent progenitor cells, the adipose stromal cells (ASCs). In this regard, considerable work has been performed to harvest and characterize this cell population as well as to investigate the mechanisms by which transplanted ASCs mediate tissue regeneration. In contrast the endogenous release of native ASCs by AT has been poorly investigated. In this work, we show that native ASCs egress from murine AT. Indeed, we demonstrated that the release of native ASCs from AT can be evidenced both using an ex vivo perfusion model that we set up and in vivo. Such a mobilization process is controlled by CXCR4 chemokine receptor. In addition, once mobilized from AT, circulating ASCs were found to navigate through lymph fluid and to home into lymph nodes (LN). Therefore, we demonstrated that, during the LN activation, the fat depot encapsulating the activated LN releases native ASCs, which in turn invade the activated LN. Moreover, the ASCs invading the LN were visualized in close physical interaction with podoplanin and ER-TR7 positive structures corresponding to the stromal network composing the LN. This dynamic was impaired with CXCR4 neutralizing antibody. Taken together, these data provide robust evidences that native ASCs can traffic in vivo and that AT might provide stromal cells to activated LNs.